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Background
In our aging society Alzheimer’s Disease (AD) is becoming
more and more prevalent while effective symptomatic
therapeutics remain limited and no cure is available.
ApoE4 is the most important genetic risk factor for AD.
Previous results by Cramer et al. [1] showed that Bexaro-
tene treatment reduced Ab in the brain of wild type and
AD model mice via an apoE-mediated clearance mechan-
ism. Bexarotene, an RXR agonist, is an FDA approved
drug for cutaneous T cell lymphoma and hence a pre-
ferred candidate for clinical testing. In this study we
attempted to replicate the data by Cramer et al. [1].
Methods
We used captisol® (Cydex Pharmaceuticals), and
HP-b-CD/ Tween to dissolve Bexarotene for administra-
tion in mice and dogs respectively. For acute experiments
we administered a single 100 mg/kg/p.o. dose of Bexaro-
tene (Ontario Chemical, Inc., Canada) to wild type male
Swiss CD1 mice and measured endogenous levels of
soluble Abx-37, Abx-38, Abx-40 and Abx-42 in brain at differ-
ent time points. In Beagle dogs we administered 25 and
100 mg/kg/p.o. Bexarotene and measured Abx-37, Abx-38,
Abx-40 and Abx-42 levels in CSF. For chronic experiments
we administered 100 mg/kg/day/p.o. Bexarotene for
19 days to 10-months-old male hAPP/PS1 mice.
Results
In contrast to the published data, we found that acute and
chronic treatment with Bexarotene had no significant
effects on Ab levels in the brain of wild type and AD
model mice and in Beagle dogs, despite high penetration
of the drug into the brain. Although behavioral alterations
were observed in AD model mice, adverse effects of the
treatment confounded these observations.
Conclusions
Drug formulation and pharmacokinetics might explain
our contradictory observations with Cramer et al. [1] at
least partly. These issues need to be resolved before
Bexarotene can be tested in AD.
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